Cargando…
Correction of HDL Dysfunction in Individuals With Diabetes and the Haptoglobin 2-2 Genotype
OBJECTIVE—Pharmacogenomics is a key component of personalized medicine. The Israel Cardiovascular Events Reduction with Vitamin E Study, a prospective placebo-controlled study, recently demonstrated that vitamin E could dramatically reduce CVD in individuals with diabetes and the haptoglobin (Hp) 2-...
Autores principales: | Asleh, Rabea, Blum, Shany, Kalet-Litman, Shiri, Alshiek, Jonia, Miller-Lotan, Rachel, Asaf, Roy, Rock, Wasseem, Aviram, Michael, Milman, Uzi, Shapira, Chen, Abassi, Zaid, Levy, Andrew P. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
American Diabetes Association
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2551691/ https://www.ncbi.nlm.nih.gov/pubmed/18599520 http://dx.doi.org/10.2337/db08-0450 |
Ejemplares similares
-
Pharmacogenomic application of the haptoglobin genotype in the treatment of HDL dysfunction
por: Schwartz, Avery, et al.
Publicado: (2009) -
Haptoglobin genotype is a determinant of survival and cardiac remodeling after myocardial infarction in diabetic mice
por: Asaf, Roy, et al.
Publicado: (2009) -
Haptoglobin Genotype and Renal Function Decline in Type 1 Diabetes
por: Costacou, Tina, et al.
Publicado: (2009) -
The Haptoglobin 1 Allele Correlates With White Matter Hyperintensities in Middle-Aged Adults With Type 1 Diabetes
por: Costacou, Tina, et al.
Publicado: (2015) -
In Vivo and In Vitro Studies Establishing Haptoglobin as a Major Susceptibility Gene for Diabetic Vascular Disease
por: Asleh, Rabea, et al.
Publicado: (2005)